Terapevticheskii arkhivTerapevticheskii arkhiv0040-36602309-5342LLC Obyedinennaya Redaktsiya3296010.26442/00403660.2019.01.000040Review ArticleSignificance of L-carnitine in internal medicineSizovaZh Msizova-klinfarma@mail.ruShikhE Vchih@mail.ruMakhovaA Aannabramova@gmail.comI.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)1501201991111412011042020Copyright © 2019, Consilium Medicum2019The review presents the results of a number of experimental and clinical studies proving the prospects of using L-carnitine in the clinic of internal diseases. Due to the antioxidant and antihypoxant properties, the additional use of L-carnitine in addition to the main etiopathogenetic therapy is prescribed by cardiologists, nephrologists, neurologists, gerontologists. Experimental studies we conducted earlier showed no effect of L-carnitine on the activity of the P450 CYP 3A4 system, which reduces the likelihood of drug-drug interaction at the level of metabolism of drugs metabolized by P450 3A4. When using L-carnitine as part of complex pharmacotherapy, the drug has an increased safety profile in comorbid patients taking L-carnitine.L-carnitinechronic heart failuremyocardial infarctionchronic renal failureinter-drug interactionantioxidantantihypoxantL-карнитинР450 CYP 3А4хроническая сердечная недостаточностьинфаркт миокардахроническая почечная недостаточностьмежлекарственное взаимодействиеантиоксидантантигипоксантP450 CYP 3А4[Кyкec В.Г., Сычев Д.А. Пepcoнaлизиpoвaннaя мeдицинa: нoвыe вoзмoжнocти для пoвышeния бeзoпacнocти фapмaкoтepaпии. Peмeдиyм. 2010;(10):38-40.][Мaxoвa A.A. Влияниe нaгpyзoчныx дoз витaминoв гpyппы B нa фapмaкoкинeтикy и фapмaкoдинaмикy НПВC: диc. … кaнд. мeд. нayк. М., 2010; 107 c.][Rebouche C.J. Carnitine. In: Shils M.E, Shike M, Ross A.C, Caballero B, Cousins R.J, eds. Modern Nutrition in Health and Disease. 10th ed. Philadelphia: Lippincott, Williams & Wilkins; 2006:537-544.][Rebouche C.J. Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism. Ann NY Acad Sci. 2004;1033:30-41.][De Grandis D, Minardi C. Acetyl-L-carnitine (levacecarnine) in the treatment of diabeic neuropathy. A long - term, randomised, double - blind, placebo - controlled study. Drugs RD. 2002;3(4):223-31.][Gross C.J, Henderson L.M, Savaiano D.A. Uptake of L-carnitine, D-carnitine and acetyl-L-carnitine by isolated guinea - pig enterocytes. Biochim Biophys Acta. 1986;886(3):425-33.][Foster D.W. The role of the carnitine system in human metabolism. Ann NY Acad Sci. 2004;1033:1-16.][Асташкин Е.И., Глезер М.Г. Роль L-карнитина в энергетичесокм обмене кардиомиоцитов и лечении заболеваний сердечно - сосудистой системы. Кардиология и сердечно - сосудистая хирургия. 2012;6(2):58-65.][Lombard K.A, Olson A.L, Nelson S.E, Rebouche C.J. Carnitine status of lactoovovegetarians and strict vegetarian adults and children. Am J Clin Nutr. 1989;50(2):301-6.][Nezu J, Tamai I, Oku A, et al. Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion - dependent carnitine transporter. Nat Genet. 1999;21(1):91-4.][Stanley C.A. Carnitine deficiency disorders in children. Ann NY Acad Sci. 2004;1033:42-51.][Seim H, Eichler K, Kleber H. L(-)-Carnitine and its precursor, gamma - butyrobetaine. In: Kramer K, Hoppe P, Packer L, eds. Nutraceuticals in Health and Disease Prevention. New York: Marcel Dekker, Inc; 2001:217-256.][Pons R, De Vivo D.C. Primary and secondary carnitine deficiency syndromes. J Child Neurol. 1995;10(Suppl 2):8-24.][Calvani M, Benatti P, Mancinelli A, et al. Carnitine replacement in end - stage renal disease and hemodialysis. Ann NY Acad Sci. 2004;1033:52-66.][Food and Nutrition Board, Institute of Medicine. Vitamin C. Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids. Washington D.C.: National Academy Press; 2000:95-185.][Costell M, O'Connor J.E, Grisolia S. Age - dependent decrease of carnitine content in muscle of mice and humans. Biochem Biophys Res Commun. 1989;161(3):1135-43.][Hagen T.M, Ingersoll R.T, Wehr C.M, et al. Acetyl-L-carnitine fed to old rats partially restores mitochondrial function and ambulatory activity. Proc Natl Acad Sci USA. 1998;95(16):9562-6.][Pesce V, Fracasso F, Cassano P, Lezza A.M, Cantatore P, Gadaleta M.N. Acetyl-L-carnitine supplementation to old rats partially reverts the age - related mitochondrial decay of soleus muscle by activating peroxisome proliferator - activated receptor gamma coactivator-1alpha - dependent mitochondrial biogenesis. Rejuvenation Res. 2010;13(2-3):148-51.][Gomez L.A, Heath S.H, Hagen T.M. Acetyl-L-carnitine supplementation reverses the age - related decline in carnitine palmitoyltransferase 1 (CPT1) activity in interfibrillar mitochondria without changing the l - carnitine content in the rat heart. Mech Ageing Dev. 2012;133(2-3):99-106.][Hagen T.M, Liu J, Lykkesfeldt J, et al. Feeding acetyl-L-carnitine and lipoic acid to old rats significantly improves metabolic function while decreasing oxidative stress. Proc Natl Acad Sci USA. 2002;99(4):1870-5.][Liu J, Head E, Gharib A.M, et al. Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: partial reversal by feeding acetyl-L-carnitine and/or R-alpha - lipoic acid. Proc Natl Acad Sci USA. 2002;99(4):2356-61.][Davini P, Bigalli A, Lamanna F, Boem A. Controlled study on L-carnitine therapeutic efficacy in post - infarction. Drugs Exp Clin Res. 1992;18(8):355-65.][Xue Y.Z, Wang L.X, Liu H.Z, Qi X.W, Wang X.H, Ren H.Z. L-carnitine as an adjunct therapy to percutaneous coronary intervention for non-ST elevation myocardial infarction. Cardiovasc Drugs Ther. 2007;21(6):445-8.][Iyer R, Gupta A, Khan A, Hiremath S, Lokhandwala Y. Does left ventricular function improve with L-carnitine after acute myocardial infarction? J Postgrad Med. 1999;45(2): 38-41.][Colonna P, Iliceto S. Myocardial infarction and left ventricular remodeling: results of the CEDIM trial. Carnitine Ecocardiografia Digitalizzata Infarto Miocardico. Am Heart J. 2000;139(2 Pt 3):124-30.][Iliceto S, Scrutinio D, Bruzzi P, et al. Effects of L-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: the L-Carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) Trial. J Am Coll Cardiol. 1995;26(2):380-7.][Tarantini G, Scrutinio D, Bruzzi P, Boni L, Rizzon P, Iliceto S. Metabolic treatment with L-Carnitine in acute anterior ST segment elevation myocardial infarction. A randomized controlled trial. Cardiology. 2006;106(4):215-23.][Семиголовский Н.Ю., Верцинский Е.К., Азанов Б.А., Иванова Е.В. Положительные инотропные свойства левокарнитина при синдроме малого выброса у больных острым инфарктом миокарда. Кардиология и cердечно - сосудистая хирургия. 2013;(3):43-6.][Глезер М.Г., Киселева А.Е., Асташкин Е.И. Влияние L-карнитина на дисперсию интервала QT у пациентов с острым коронарным синдромом. Кардиология. 2015;55(3):4-9.][Глезер М.Г., Киселева А.Е., Асташкин Е.И Влияние L-карнитина на ЧCC и QTс у пациентов с острым коронарным синдромом. Сердце. 2015;14(2/82):78-84.][Глезер М.Г., Киселева А.Е., Прокофьева Е.Б., Асташкин Е.И. Влияние L-карнитина на эхокардиографические показатели у пациентов с острым коронарным синдромом. Журнал Сердечная Недостаточность. 2015;16(4):234-40.][Асташкин Е.И., Глезер М.Г. Влияние L-карнитина на оксидативный стресс при сердечно - сосудистых заболеваниях. Медицинский Совет. 2016;10:94-100.][Асташкин Е.И., Глезер М.Г., Орехова Н.С., Грачев С.В., Киселева А.Е. Влияние L-карнитина на образование радикалов кислорода фагоцитами крови пациентов с постинфарктным кардиосклерозом. Кардиоваскулярная терапия и профилактика. 2016;15(5):28-32.][Rizos I. Threeyear survival of patients with heart failure caused by dilated cardiomyopathy and L-carnitine administration. Am Heart J. 2000;139(2 Pt 3):120-3.][Xiaolong Song, Huiyan Qu, Zongguo Yang, Jingfeng Rong, Wan Cai and Hua Zhou. Efficacy and Safety of L-Carnitine Treatment for Chronic Heart Failure: A Meta-Analysis of Randomized Controlled Trials. BioMed Research International. 2017;(2017). Article ID 6274854, 11 p. doi:10.1155/2017/6274854][Cacciatore L, Cerio R, Ciarimboli M, et al. The therapeutic effect of L-carnitine in patients with exercise - induced stable angina: a controlled study. Drugs Exp Clin Res. 1991;17(4):225-35.][Cherchi A, Lai C, Angelino F, et al. Effects of L-carnitine on exercise tolerance in chronic stable angina: a multicenter, double - blind, randomized, placebo controlled crossover study. Int J Clin Pharmacol Ther Toxicol. 1985;23(10):569-72.][Iyer R.N, Khan A.A, Gupta A, Vajifdar B.U, Lokhandwala Y.Y. L-carnitine moderately improves the exercise tolerance in chronic stable angina. J Assoc Physicians India. 2000;48(11):1050-2.][Di Nicolantonio J.J, Lavie C.J, Fares H, et al. L-carnitine in the secondary prevention of cardiovascular disease: systematic review and meta - analysis. Mayo Clin Proc. 2013;88(6):544-51.][Guarnieri G, Situlin R, Biolo G. Carnitine metabolism in uremia. Am J Kidney Dis. 2001;38(4 Suppl 1):63-7.][Hurot J.M, Cucherat M, Haugh M, Fouque D. Effects of L-carnitine supplementation in maintenance hemodialysis patients: a systematic review. J Am Soc Nephrol. 2002;13(3):708-14.][Kazmi W.H, Obrador G.T, Sternberg M, et al. Carnitine therapy is associated with decreased hospital utilization among hemodialysis patients. Am J Nephrol. 2005;25(2):106-15.][Weinhandl E.D, Rao M, Gilbertson D.T, Collins A.J, Pereira B.J. Protective effect of intravenous levocarnitine on subsequent - month hospitalization among prevalent hemodialysis patients, 1998 to 2003. Am J Kidney Dis. 2007;50(5):803-12.][Clinical practice guidelines for nutrition in chronic renal failure. K/DOQI, National Kidney Foundation. Am J Kidney Diseases. 2000;35(6 Suppl 2):1-140.][Eknoyan G, Latos D.L, Lindberg J. Practice recommendations for the use of L-carnitine in dialysis - related carnitine disorder. National Kidney Foundation Carnitine Consensus Conference. Am J Kidney Dis. 2003;41(4):868-76.][Schreiber B. Safety of oral carnitine in dialysis patients. Semin Dial. 2002;15(1):7][Wei X-J, Han M, Wei G-C, Duan C-H. Prognostic value of cerebrospinal fluid free fatty acid levels in patients with acute ischemic stroke. Frontiers in Human Neuroscience. 2015;9:402. doi: 10.3389/fnhum.2015.00402.][Головкин В., Зуев А., Привалова М. и др. Когнитивные нарушения и кардиореспираторная дисфункция при дисциркуляторной энцефалопатии с кардиоцеребральным синдромом. Врач. 2018;29(4):51-3. doi: 10.29296/25877305-2018-04-09][Гусев Е.И., Кузин В.М., Колесникова Т.Н. и др. Карнитин - ведущий фактор регенерации нервной ткани. Медицинский информационный вестник. 1999 (февраль):11-23.][Бодыхов М.К., Стаховская Л.В., Салимов К.А., Сун Чер И. Оценка безопасности и эффективности препарата «Элькар» (левокарнитин) у пациентов в остром периоде ишемического инсульта в каротидной системе. РМЖ - Неврология. 2011;11:3-6.][Чичановская Л.В., Бахарева О.Н., Сорокина К.Б. Исследование безопасности и эффективности L-карнитина у больных в раннем восстановительном периоде ишемического инсульта. Журнал неврологии и психиатрии им С.С. Корсакова. 2017;12(Вып. 2):65-9.][Makhova A.A, Shich E.V, Kukes V.G, Sizova O.S, Ramenskaya G.V, Shumyantseva V.V, Bulko T.V, Archakov A.I, Usanov S.A. Electroanalysis of cytochrome P450 3A4 catalytic properties with nanostructured electrodes: the influence of vitamin B group on diclofenac metabolism. BioNanoScience. 2011;1(1-2):46-52.][Махова А.А., Шумянцева В.В., Ших Е.В., Булко Т.В., Супрун Е.В., Кузиков А.В., Кукес В.Г., Арчаков А.И. Регуляция активности ферментов метаболизма лекарственных препаратов - цитохромов Р450 3А4 и 2С9 - биологически активными соединениями. Молекулярная медицина. 2013;(5):49-53.]